Balboa Diego, Otonkoski Timo
University of Helsinki, Research Programs Unit, Molecular Neurology and Biomedicum Stem Cell Center, Finland.
University of Helsinki, Research Programs Unit, Molecular Neurology and Biomedicum Stem Cell Center, Finland; Children's Hospital, University of Helsinki and Helsinki University Central Hospital, Finland.
Best Pract Res Clin Endocrinol Metab. 2015 Dec;29(6):899-909. doi: 10.1016/j.beem.2015.10.012. Epub 2015 Oct 30.
Although similar, mouse and human pancreatic development and beta cell physiology have significant differences. For this reason, mouse models present shortcomings that can obscure the understanding of human diabetes pathology. Progress in the field of human pluripotent stem cell (hPSC) differentiation now makes it possible to derive unlimited numbers of human beta cells in vitro. This constitutes an invaluable approach to gain insight into human beta cell development and physiology and to generate improved disease models. Here we summarize the main differences in terms of development and physiology of the pancreatic endocrine cells between mouse and human, and describe the recent progress in modeling diabetes using hPSC. We highlight the need of developing more physiological hPSC-derived beta cell models and anticipate the future prospects of these approaches.
尽管小鼠和人类的胰腺发育及β细胞生理学有相似之处,但也存在显著差异。因此,小鼠模型存在一些缺点,可能会妨碍对人类糖尿病病理学的理解。人类多能干细胞(hPSC)分化领域的进展现在使得在体外获得无限数量的人类β细胞成为可能。这是深入了解人类β细胞发育和生理学以及生成改进的疾病模型的一种非常宝贵的方法。在这里,我们总结了小鼠和人类胰腺内分泌细胞在发育和生理学方面的主要差异,并描述了使用hPSC建立糖尿病模型的最新进展。我们强调了开发更具生理学意义的hPSC衍生β细胞模型的必要性,并展望了这些方法的未来前景。